The phosphoinositide 3-kinase/serine–threonine protein kinase AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway is frequently deregulated in human cancer [1] and is therefore a promising target for the development of new therapies [2, 3]. This evidence concerns the gene AKT1 and cancer.